<DOC>
	<DOCNO>NCT00354328</DOCNO>
	<brief_summary>This study examine relationship certain measure heart function exercise capacity patient hypertrophic cardiomyopathy ( HCM ) . Patients participate NHLBI study 01-H-0006 ( `` Double Blind Placebo-Controlled Study Pirfenidone - A Novel Anti-Fibrotic Drug - Symptomatic Patients Hypertrophic Cardiomyopathy Associated Left Ventricular Diastolic Dysfunction '' ) 96-H-0144 ( `` Double Blind Placebo-Controlled Study Long-Term Effects Angiotensin-Converting Enzyme Inhibition ( Enalapril ) Angiotensin II Receptor Blockade ( Losartan ) Genetically-Induced Left Ventricular Diastolic Dysfunction '' ) eligible study . Data echocardiogram measure leave ventricular pressure obtain patient study analyze current study assess influence exercise capacity . No additional test , treatment procedure require . Information study may help development improve drug treatment HCM .</brief_summary>
	<brief_title>Heart Function Exercise Capacity Patients With Hypertrophic Cardiomyopathy</brief_title>
	<detailed_description>NIH Protocols 01-H-0066 , Double Blind Placebo Controlled Study Pirfenidone A Novel Anti-Fibrotic Drug Symptomatic patient Hypertrophic Cardiomyopathy ( HCM ) Associated leave Ventricular Diastolic Dysfunction 96-H-0144 , Double Blind Placebo-Controlled Study Long-Term Effects Angiotensin Converting Enzyme Inhibition ( Enalapril ) Angiotensin II Receptor Blockade ( Losartan ) On Genetically-Induced Left Ventricular Diastolic Dysfunction undertaken ass effect therapeutic intervention leave ventricular ( LV ) diastolic function . The relationship baseline measure diastolic function assess noninvasive modality Doppler echocardiography radionuclide angiography , qualitative objective measure functional capacity patient without LV outflow tract obstruction report . In protocol look measure LV geometry , relaxation novel index ventricular compliance may influence measure exercise capacity . In case , use pre-existing baseline data obtain informed consent part protocol .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<criteria>Eligibility criterion list ; Analysis data previous study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>HCM</keyword>
	<keyword>Echocardiography</keyword>
	<keyword>Diastolic Dysfunction</keyword>
	<keyword>Enalapril</keyword>
</DOC>